National Heart Foundation of Australia

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event

BackgroundPatients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk. MethodsIn this phase 3, randomized, placebo-con...

Integration of lipidomic and polygenic risk scores within contemporary clinical cardiovascular risk assessment pathways: a multi-cohort development and validation study

Background Guideline-recommended clinical risk scores such as AusCVDRisk underestimate cardiovascular disease (CVD) risk in a substantial proportion of individuals who later experience events, with up to 65% initially classified as low or intermediate risk. This limitation is mos...

DNA metabarcoding improves detection of rare and volant prey in the diet of feral cats (Felis catus)

Context Cats (Felis catus) have contributed to the extinctions of more than 60 vertebrates and continue to be a major conservation threat globally. Conservation managers traditionally record the diet of cats from morphological (manual) searches of stomach or scat samples. However...